SummaryThe U.S. FDA has suspended the license for Valneva’s chikungunya vaccine Ixchiq after reports of severe side effects, including deaths and hospitalizations. The move comes amid rising global chikungunya outbreaks, with the U.S. also issuing a travel advisory for China. Valneva will halt U.S. sales but continue global distribution.